Evidence map›Paper›PMID 32908574›Full record

ArticleComputational and mathematical methods in medicine2020

A Model for SARS-CoV-2 Infection with Treatment.

Amar Nath Chatterjee, Fahad Al Basir

Abstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. From Legacy to Innovation: Pidotimod's Expanding Therapeutic Horizon.Mediterranean journal of hematology and infectious diseases · 2025
    Review
  2. Pidotimod in pediatrics: new evidence and future perspectives.Multidisciplinary respiratory medicine · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amar Nath ChatterjeeDepartment of Mathematics, K.L.S. College, Nawada, Magadh University, Bodh Gaya, Bihar 805110, India.ORCID https://orcid.org/0000-0002-3007-0144
Fahad Al BasirDepartment of Mathematics, Asansol Girls' College, Asansol-4, West Bengal 713304, India.ORCID https://orcid.org/0000-0003-2568-0287

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current emergence of coronavirus (SARS-CoV-2) puts the world in threat. The structural research on the receptor recognition by SARS-CoV-2 has identified the key interactions between SARS-CoV-2 spike protein and its host (epithelial cell) receptor, also known as angiotensin-converting enzyme 2 (ACE2). It controls both the cross-species and human-to-human transmissions of SARS-CoV-2. In view of this, we propose and analyze a mathematical model for investigating the effect of CTL responses over the viral mutation to control the viral infection when a postinfection immunostimulant drug (pidotimod) is administered at regular intervals. Dynamics of the system with and without impulses have been analyzed using the basic reproduction number. This study shows that the proper dosing interval and drug dose both are important to eradicate the viral infection.

Indexed as

BetacoronavirusModels, BiologicalAdjuvants, ImmunologicAngiotensin-Converting Enzyme 2Basic Reproduction NumberComputer SimulationCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDose-Response Relationship, DrugHost Microbial InteractionsHumansMathematical ConceptsMutationPandemicsPeptidyl-Dipeptidase AACE2 protein, humanAdjuvants, ImmunologicAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase ApidotimodPyrrolidonecarboxylic AcidReceptors, VirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Thiazolidines

Identifiers

PMID32908574
PMCPMC7463400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.